Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Assertio stock

Learn how to easily invest in Assertio stock.

Assertio Holdings Inc
+ $0.03 ( + 1.37%)

Assertio Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Assertio shares (ASRT) are listed on the NASDAQ and all prices are listed in US Dollars. Assertio employs 27 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Assertio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ASRT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Assertio stock price (NASDAQ: ASRT)

Use our graph to track the performance of ASRT stocks over time.

Assertio shares at a glance

Information last updated 2022-01-17.
Latest market close$2.19
52-week range$0.85 - $5.80
50-day moving average $1.80
200-day moving average $1.52
Wall St. target price$4.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.78

Buy Assertio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Assertio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Assertio price performance over time

Historical closes compared with the close of $2.19 from 2022-01-24

1 week (2022-01-18) 2.34%
1 month (2021-12-23) -0.45%
3 months (2021-10-25) 119.00%
6 months (2021-07-23) 75.20%
1 year (2021-01-25) 217.35%
2 years (2020-01-24) 95.54%
3 years (2019-01-25) 4.18
5 years (2017-01-25) 18.09

Is Assertio stock undervalued or overvalued?

Valuing Assertio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Assertio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Assertio's EBITDA

Assertio's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34.1 million.

The EBITDA is a measure of a Assertio's overall financial performance and is widely used to measure a its profitability.

Assertio financials

Revenue TTM $109.7 million
Operating margin TTM 4.92%
Gross profit TTM $92.3 million
Return on assets TTM 1.07%
Return on equity TTM -35%
Profit margin -27.56%
Book value $2.17
Market capitalisation $104 million

TTM: trailing 12 months

Assertio share dividends

We're not expecting Assertio to pay a dividend over the next 12 months.

Have Assertio's shares ever split?

Assertio's shares were split on a 1:4 basis on 17 May 2021. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Assertio shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Assertio shares which in turn could have impacted Assertio's share price.

Assertio share price volatility

Over the last 12 months, Assertio's shares have ranged in value from as little as $0.85 up to $5.8. A popular way to gauge a stock's volatility is its "beta".

ASRT.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Assertio's is 1.664. This would suggest that Assertio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Assertio overview

Assertio Holdings, Inc. , a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, an NSAID for relief of mild to moderate acute pain; and SPRIX, an NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020.

Frequently asked questions

What percentage of Assertio is owned by insiders or institutions?
Currently 2.362% of Assertio shares are held by insiders and 14.436% by institutions.
How many people work for Assertio?
Latest data suggests 27 work at Assertio.
When does the fiscal year end for Assertio?
Assertio's fiscal year ends in December.
Where is Assertio based?
Assertio's address is: 100 South Saunders Road, Lake Forest, IL, United States, 60045
What is Assertio's ISIN number?
Assertio's international securities identification number is: US04546C2052
What is Assertio's CUSIP number?
Assertio's Committee on Uniform Securities Identification Procedures number is: 04545L107

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site